Skip to main content

Novo Nordisk is dedicated to supporting your patients.

Explore our services, tools, and resources. Or, connect with a Novo Nordisk representative to learn more.

QuickCheck™.

Magnifying glass of a dollar sign
Magnifying glass of a dollar sign

QuickCheck™ offers benefits verification. A NovoSecure™ Specialist assists to verify coverage, and usually within 4 hours, your office will receive the Summary of Benefits.

Product support.

Novosecure™ website home page

Novo Nordisk offers services through NovoSecure™, a support program designed to assist your qualifying patients throughout the reimbursement process.

Patient education.

 Novoeight® brochure

Our informative educational resources can help your patients learn more about living with hemophilia. Download, share, or order for your office. 

Patient stories.

Team Novo8™ logo

Team Novo8™ is a group of patients who switched to Novoeight® and spend their time helping others with hemophilia A. Hear more about their mission, and how your patients can benefit from their experiences.

  • Novoeight® Facebook Page

    The Novoeight® Facebook page provides your patients with helpful information about Novoeight®, from product news to highlights of people and events that may interest them.

Have a question? We’re here to help.

Enter your zip code to search for a Novo Nordisk representative.
 

Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information.